A new trading day began on Tuesday, with Immunome Inc (NASDAQ: IMNM) stock price down -2.95% from the previous day of trading, before settling in for the closing price of $19.64. IMNM’s price has ranged from $5.15 to $20.46 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -38.15% over the past five years. Meanwhile, its annual earnings per share averaged 55.75%. With a float of $89.10 million, this company’s outstanding shares have now reached $91.71 million.
Immunome Inc (IMNM) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 2.85%, while institutional ownership is 96.17%. The most recent insider transaction that took place on Jun 03 ’25, was worth 46,900. In this transaction Director of this company bought 5,000 shares at a rate of $9.38, taking the stock ownership to the 36,415 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Director bought 7,800 for $7.78, making the entire transaction worth $60,684. This insider now owns 31,415 shares in total.
Immunome Inc (IMNM) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -1.11 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.96% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Here are Immunome Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 180.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Immunome Inc (NASDAQ: IMNM) saw its 5-day average volume 1.21 million, a positive change from its year-to-date volume of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 73.33%.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 88.13%, which indicates a significant increase from 61.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.20 in the past 14 days, which was higher than the 0.91 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.32, while its 200-day Moving Average is $10.82. Nevertheless, the first resistance level for the watch stands at $19.63 in the near term. At $20.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.51. If the price goes on to break the first support level at $18.76, it is likely to go to the next support level at $18.46. Assuming the price breaks the second support level, the third support level stands at $17.88.
Immunome Inc (NASDAQ: IMNM) Key Stats
With a market capitalization of 1.75 billion, the company has a total of 91,710K Shares Outstanding. Currently, annual sales are 9,040 K while annual income is -292,960 K. The company’s previous quarter sales were 4,020 K while its latest quarter income was -43,400 K.
